Background Rifapentine-based regimens have potent antimycobacterial activity that may allow
for a shorter course in patients with drug-susceptible pulmonary tuberculosis. Methods In …

Background Tuberculosis is the world's leading infectious disease killer. We aimed to
识别短,安全的drug regimens for the treatment of tuberculosis. Methods We did a …

Rationale: Rifampin at a dose of 10 mg/kg was introduced in 1971 based on pharmacokinetic,
toxicity, and cost considerations. Available data in mice and humans showed that an …

PA-824 is a novel nitroimidazo-oxazine being evaluated for its potential to improve tuberculosis
(TB) therapy. This randomized study evaluated safety, tolerability, pharmacokinetics, and …

PA-824 is a novel nitroimidazo-oxazine under evaluation as an antituberculosis agent. A
dose-ranging randomized study was conducted to evaluate the safety, tolerability, …

Objectives SQ109, an asymmetrical diamine, is a novel anti-TB drug candidate. This first
study in patients was done to determine safety, tolerability, pharmacokinetics and …

Linezolid is increasingly used for the treatment of tuberculosis resistant to first-line agents,
but the most effective dosing strategy is yet unknown. From November 2014 to November …

Background Accumulating data indicate that higher rifampicin doses are more effective and
shorten tuberculosis (TB) treatment duration. This study evaluated the safety, tolerability, …

Shorter, more potent regimens are needed for tuberculosis. The nitroimidazole pretomanid
was recently approved for extensively drug-resistant tuberculosis in combination with …

Drug susceptibility testing (DST) patterns of Mycobacterium tuberculosis (MTB) from patients
with rifampicin-resistant tuberculosis (RR-TB) or multidrug-resistant TB (MDR-TB; or …